Diaceutics PLC (DXRX) · 2026-09-24
Diaceutics has expanded its existing multi-year Relay partnership with Syndax Pharmaceuticals to support commercialisation of a diagnostic-driven acute leukaemia therapy. Financial terms are confidential, so the revenue impact is not disclosed.
Diaceutics PLC (DXRX) · 2026-09-22
Diaceutics grew H1 revenue 20% to £17.5m and adjusted EBITDA to £1.1m, with positive free cash flow. The Board reiterated FY2026 expectations, supported by 107% revenue visibility, though pipeline conversion and H2 execution remain necessary.
Diaceutics PLC (DXRX) · 2026-09-08
Diaceutics will announce unaudited results for the half year ended 30 June 2026 on 22 September 2026, providing the next scheduled update on trading and financial performance.
Diaceutics PLC (DXRX) · 2026-07-29
Diaceutics reported H1 2026 revenue of £17.5m, up 20%, while annual recurring revenue rose 75% to £28.8m and weighted pipeline lifted FY 2026 revenue visibility to 91%.
Diaceutics PLC (DXRX) · 2026-07-03
Diaceutics said it issued 5,354 shares to the UK Trust on 2 July 2026 to settle matched share awards under its UK SIP, with awards matched 1:1 against employee purchases.
Diaceutics PLC (DXRX) · 2026-05-26
Diaceutics reported a return to profitability for FY 2025 as revenue grew 24% to £38.4 million on a constant currency basis. Adjusted EBITDA rose 80% to £7.6 million while the order book reached a record £38.9 million, supporting management confidence for 2026.